Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Dr. Reddy's Laboratories Limited is a drug manufacturers-specialty & generic business based in the US. DrReddys Laboratories shares (RDY) are listed on the NYSE and all prices are listed in US Dollars. DrReddys Laboratories employs 22,739 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$63.84|
|52-week range||$56.97 - $74.75|
|50-day moving average||$65.67|
|200-day moving average||$68.00|
|Wall St. target price||$77.85|
|Dividend yield||$25 (38.19%)|
|Earnings per share (TTM)||$1.38|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-1.34%|
|1 month (2021-09-20)||-1.83%|
|3 months (2021-07-20)||-10.83%|
|6 months (2021-04-20)||-5.23%|
|1 year (2020-10-20)||-6.78%|
|2 years (2019-10-18)||64.92%|
|3 years (2018-10-19)||83.92%|
|5 years (2016-10-20)||38.60%|
Valuing DrReddys Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddys Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DrReddys Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, DrReddys Laboratories shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DrReddys Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6592. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddys Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DrReddys Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.2 billion.
The EBITDA is a measure of a DrReddys Laboratories's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$194.7 billion|
|Operating margin TTM||16.15%|
|Gross profit TTM||$103.1 billion|
|Return on assets TTM||7.42%|
|Return on equity TTM||10.09%|
|Market capitalisation||$11 billion|
TTM: trailing 12 months
There are currently 975,394 DrReddys Laboratories shares held short by investors – that's known as DrReddys Laboratories's "short interest". This figure is 14.9% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting DrReddys Laboratories shares can be evaluated.
DrReddys Laboratories's "short interest ratio" (SIR) is the quantity of DrReddys Laboratories shares currently shorted divided by the average quantity of DrReddys Laboratories shares traded daily (recently around 112632.10161663). DrReddys Laboratories's SIR currently stands at 8.66. In other words for every 100,000 DrReddys Laboratories shares traded daily on the market, roughly 8660 shares are currently held short.
However DrReddys Laboratories's short interest can also be evaluated against the total number of DrReddys Laboratories shares, or, against the total number of tradable DrReddys Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DrReddys Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DrReddys Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0083% of the tradable shares (for every 100,000 tradable DrReddys Laboratories shares, roughly 8 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DrReddys Laboratories.
Find out more about how you can short DrReddys Laboratories stock.
Dividend payout ratio: 21.65% of net profits
Recently DrReddys Laboratories has paid out, on average, around 21.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddys Laboratories shareholders could enjoy a 0.51% return on their shares, in the form of dividend payments. In DrReddys Laboratories's case, that would currently equate to about $25 per share.
While DrReddys Laboratories's payout ratio might seem low, this can signify that DrReddys Laboratories is investing more in its future growth.
DrReddys Laboratories's most recent dividend payout was on 10 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 7 July 2021 (the "ex-dividend date").
DrReddys Laboratories's shares were split on a 2:1 basis on 6 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddys Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddys Laboratories shares which in turn could have impacted DrReddys Laboratories's share price.
Over the last 12 months, DrReddys Laboratories's shares have ranged in value from as little as $56.9679 up to $74.7492. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddys Laboratories's is 0.0987. This would suggest that DrReddys Laboratories's shares are less volatile than average (for this exchange).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.